Global Hyperlipidemia Drugs Market Analysis (2016-2022): AstraZeneca, Merck, Pfizer, Daiichi Sankyo, Amgen and Sanofi are Profiled

News provided by

Nov 15, 2018, 18:00 ET

DUBLIN, Nov. 15, 2018 /PRNewswire/ --

The "Hyperlipidemia Drugs Market Analysis Report by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination), and Segment Forecasts, 2016 - 2022" report has been added to ResearchAndMarkets.com's offering.

The global hyperlipidemia drugs market size is expected reach USD 22.6 billion by 2022, expanding at a CAGR of 2.3% during the forecast period.

Several factors, such as increase in target population and growth in awareness about risk of cardiovascular diseases (CVD) due to persistent hypercholesterolemia, are stoking the growth of the market.

Target population of antihyperlipidemic drugs is broadly divided into statin users and nonstatin users. The revenue share of statin users has been declining. The nonstatin users segment consists of statin intolerant and nonresponsive population as well as familial hyperlipidemia (FH) population. Nonstatin users are seeking high-efficacy alternatives and this is anticipated to boost the revenue of this segment.

Upcoming patent expirations are expected to lead to greater genericization in the market, mostly among statins, cholesterol absorption inhibitors, and combination drugs. However, new product launches are anticipated to continue to drive the market. Several novel mechanisms of action such as ACL inhibition, DGAT2 inhibition, and anti-ANGPTL-3 are being investigated for their potential for treatment of hyperlipidemia as well as for reducing the risk of CVD.

Key Findings

Key Topics Covered

Statins dominated the drug classes in 2016 owing to their high usage as the first line of therapy
Recent launch of PCSK9 inhibitors, such as Repatha and Praluent, is likely to change the current therapeutic scenario due to their improved efficacy and safety profile
PCSK9 inhibitors are expected to displace existing expensive therapies, lomitapide, and mipomersen for the treatment of homozygous FH patients
Europe was the leading regional market in 2016. It is estimated to maintain its dominance till 2022 owing to high prevalence of hypercholesterolemia
There are fewer growth opportunities in Japan due to unavailability of key pipeline drugs such as bempedoic acid
AstraZeneca, Merck & Co., Inc., Pfizer, Inc., DAIICHI SANKYO COMPANY, LIMITED, Amgen, Inc., and Sanofi are some of the key players operating in this market
Amgen, Inc., Sanofi, and Esperion are expected to have the highest shares in this market by 2022

Chapter 1 Research Methodology
1.1 Information procurement
1.2 Information or Data Analysis
1.2.1 Market formulation & validation

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Disease Primer and Epidemiology
3.1 Disease Primer
3.1.1 Types:
3.1.1.1 Type I
3.1.1.2 Type II
3.1.1.3 Type III
3.1.1.4 Type IV
3.1.1.5 Type V
3.1.2 Complications
3.2 Epidemiology by Indications
3.3 Current Prevalence for Seven Major Markets (U.S., Japan, & EU5)
3.4 Current Incidence for Seven Major Markets (U.S., Japan, & EU5)
3.5 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, & EU5)

Chapter 4 Global Hyperlipidemia Drugs Market Overview
4.1 Introduction and Market Overview
4.2 Patent Expiry Schedule
4.3 Drivers and Challenges
4.4 M&A, Deal Landscape (2013 - 2017 YTD)
4.5 Pricing and Reimbursement
4.6 SWOT analysis

Chapter 5 Hyperlipidemia Drugs Market: Pipeline Intelligence
5.1 Pipeline Landscape
5.2 Promising Drugs in Pipeline

Chapter 6 Company Profiles
6.1 AstraZeneca
6.2 Merck
6.3 Pfizer
6.4 Daiichi Sankyo
6.5 Amgen
6.6 Sanofi

Chapter 7 Market Outlook
7.1 What the future holds
7.2 Winners and Losers
7.3 Emerging Companies
7.4 The Road Ahead

For more information about this report visit https://www.researchandmarkets.com/research/vrb2ph/global?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets